JMJD6 and metastatic malignant neoplasm in the lymph nodes: In addition, ESCC patients with lymph node metastasis (N1-3), poorly differentiated, and a high American Joint Committee on Cancer (AJCC) 7th stage (stage III) had a significantly higher JMJD6 expression than those without lymph node metastasis (N0), with well and moderate differentiation and a lower 7th AJCC stage (stage I/II) (p < 0.05, Table 2).